Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amifostine with DHAP in Lymphoma
NCT00003143Phase 2Completed
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Nov 1997
- Primary completion
- Dec 2000
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of amifostine in non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) (2 arms), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoints: Reduction in hematologic toxicity and Mobilization of peripheral progenitor stem cells. Started Nov 1997; status: completed.
02
Drugs
amifostine
03
Conditions
non-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00003143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003143.